Autoantibodies against oxidised low-density lipoprotein in patients with obstructive sleep apnoea.
Autoantibodies against oxidised low-density lipoprotein (OxLDL-Abs) have been proposed to be an indicator of endothelial dysfunction and a novel tool for finding individuals with a high cardiovascular risk. In a cross-sectional study, OxLDL-Abs were measured in 297 patients with obstructive sleep apnoea (OSA) and 54 controls using an enzyme-linked immunosorbent assay. The autoantibodies were increased in patients with OSA when compared to controls (age, body mass index (BMI) and gender adjusted, p = 0.001). However, within the OSA patients, OxLDL-Abs were not related to smoking, hypertension or BMI, and there was a weak negative correlation (r = -0.16, P = 0.007) between age and levels of OxLDL-Abs. In conclusion, at present the measurement OxLDL-Abs still remains a method for basic research and is not applicable for screening of at-risk patients with OSA.
Saarelainen
S
S
Department of Pulmonary Diseases, Tampere University Hospital, Pikonlinna, Finland. ssaarelainen@tays.fi
Lehtimäki
T
T
Jaak-kola
O
O
Poussa
T
T
Nikkilä
M
M
Solakivi
T
T
Nieminen
M M
MM
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis*; D015992:Body Mass Index; D008078:Cholesterol, LDL / Q000032:analysis; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012891:Sleep Apnea Syndromes / Q000276:immunology*; D012907:Smoking
D001323:Autoantibodies; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein